Literature DB >> 27099834

Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer.

Furio Pacini1.   

Abstract

Entities:  

Year:  2016        PMID： 27099834      PMCID： PMC4836123          DOI： 10.1159/000442880

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN： 2235-0640


× No keyword cloud information.
  8 in total

1.  A low postoperative nonstimulated serum thyroglobulin level excludes the presence of persistent disease in low-risk papillary thyroid cancer patients: implication for radioiodine indication.

Authors:  Pedro W Rosario; Gabriela F Mourão; Thassio Leonardo Siman; Maria Regina Calsolari
Journal:  Clin Endocrinol (Oxf)       Date:  2014-12-29       Impact factor: 3.478

Review 2.  Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.

Authors:  C Nascimento; I Borget; A Al Ghuzlan; D Deandreis; L Chami; J P Travagli; D Hartl; J Lumbroso; C Chougnet; L Lacroix; E Baudin; M Schlumberger; S Leboulleux
Journal:  Endocr Relat Cancer       Date:  2011-03-03       Impact factor: 5.678

3.  Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006.

Authors:  Briseis Aschebrook-Kilfoy; Mary H Ward; Mona M Sabra; Susan S Devesa
Journal:  Thyroid       Date:  2010-12-27       Impact factor: 6.568

4.  Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.

Authors:  Claire Schvartz; Franck Bonnetain; Sandrine Dabakuyo; Mélanie Gauthier; Adèle Cueff; Sandrine Fieffé; Jean-Marie Pochart; Inna Cochet; Elodie Crevisy; Audrey Dalac; Dimitri Papathanassiou; Michel Toubeau
Journal:  J Clin Endocrinol Metab       Date:  2012-02-16       Impact factor: 5.958

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 6.  Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report.

Authors:  Furio Pacini; Martin Schlumberger; Clive Harmer; Gertrud G Berg; Ohad Cohen; Leonidas Duntas; François Jamar; Barbara Jarzab; Eduard Limbert; Peter Lind; Cristoph Reiners; Franco Sanchez Franco; Johannes Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2005-11       Impact factor: 6.664

7.  Recurrence after treatment of micropapillary thyroid cancer.

Authors:  Douglas S Ross; Danielle Litofsky; Kenneth B Ain; Thomas Bigos; James D Brierley; David S Cooper; Bryan R Haugen; Jacqueline Jonklaas; Paul W Ladenson; James Magner; Jacob Robbins; Monica C Skarulis; David L Steward; Harry R Maxon; Steven I Sherman
Journal:  Thyroid       Date:  2009-10       Impact factor: 6.568

8.  Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience.

Authors:  E Baudin; J P Travagli; J Ropers; F Mancusi; G Bruno-Bossio; B Caillou; A F Cailleux; J D Lumbroso; C Parmentier; M Schlumberger
Journal:  Cancer       Date:  1998-08-01       Impact factor: 6.860
  8 in total
  2 in total

1.  [Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?]

Authors:  Amir Kurtaran; Brigitta Schmoll-Hauer; Christina Tugendsam
Journal:  Wien Med Wochenschr       Date:  2019-12-03

2.  Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study.

Authors:  Seong Young Kwon; Sang-Woo Lee; Eun Jung Kong; Keunyoung Kim; Byung Il Kim; Jahae Kim; Heeyoung Kim; Seol Hoon Park; Jisun Park; Hye Lim Park; So Won Oh; Kyoung Sook Won; Young Hoon Ryu; Joon-Kee Yoon; Soo Jin Lee; Jong Jin Lee; Ari Chong; Young Jin Jeong; Ju Hye Jeong; Young Seok Cho; Arthur Cho; Gi Jeong Cheon; Eun Kyoung Choi; Jae Pil Hwang; Sang Kyun Bae
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-10       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.